Literature DB >> 32050643

Milk Fat Globule-EGF Factor 8 Contributes to Progression of Hepatocellular Carcinoma.

Duck Sung Ko1, Su Hyun Kim2, Ji Young Park1, Gyunggyu Lee1, Hyo Jin Kim1, Gyeongmin Kim1, Kyun You Chi1, Ilsoo Kim1, Jinseok Lee1, Kyu-Yeoun Won2, Jiyou Han3, Jeongsang Son1, Dong-Hun Woo4, Choongseong Han4, Jong-Hoon Kim1.   

Abstract

Milk fat globule-EGF factor 8 (MFG-E8) is an anti-inflammatory glycoprotein that mediates a wide spectrum of pathophysiological processes. MFG-E8 has been studied as a key regulator of cancer cell invasion, migration, and proliferation in different tissues and organs. However, potential roles of MFG-E8 in the growth and progression of liver cancer have not been investigated to date. Here, we analyzed 33 human hepatocellular carcinoma (HCC) samples and found that levels of MFG-E8 expression were significantly higher in HCC cells than in normal liver tissues. In addition, our in vitro gain-of-function study in three different HCC cell lines revealed that overexpression of MFG-E8 promoted the proliferation and migration of HCC cells, as determined by RT-qPCR, MTT assays, and wound healing analyses. Conversely, an MFG-E8 loss-of function study showed that proliferation capacity was significantly reduced by MFG-E8 knockdown in HCC cells. Additionally, MFG-E8 activity-neutralizing antibodies profoundly inhibited both migration and proliferation of HCC cells, attenuating their tumorigenic properties. These reductions in migration and proliferation were rescued by treatment of HCC cells with recombinant MFG-E8 protein. Furthermore, an in vivo HCC xenograft study showed that the number of proliferating HCC cells and tumor volume/weight were all significantly increased by MFG-E8 overexpression, compared to control mice. These results clearly show that MFG-E8 plays an important role in HCC progression and may provide a basis for future mechanistic studies and new strategies for the treatment of liver cancer.

Entities:  

Keywords:  Hepatocellular carcinoma; migration; milk fat globule-EGF factor 8; proliferation

Year:  2020        PMID: 32050643     DOI: 10.3390/cancers12020403

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  8 in total

1.  MFG-E8 Knockout Aggravated Nonalcoholic Steatohepatitis by Promoting the Activation of TLR4/NF-κB Signaling in Mice.

Authors:  Jun Hu; Hui Du; Yinglin Yuan; Peipei Guo; Junxia Yang; Xinru Yin; Jin Liu; Shengwang Wu; Jingyuan Wan; Xia Gong
Journal:  Mediators Inflamm       Date:  2022-06-20       Impact factor: 4.529

2.  Autoregulation of insulin receptor signaling through MFGE8 and the αvβ5 integrin.

Authors:  Ritwik Datta; Carlos O Lizama; Amin K Soltani; William Mckleroy; Michael J Podolsky; Christopher D Yang; Tony L Huynh; Kelly M Cautivo; Biao Wang; Suneil K Koliwad; Nada A Abumrad; Kamran Atabai
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-04       Impact factor: 11.205

Review 3.  Dairy consumption and hepatocellular carcinoma risk.

Authors:  Bodo C Melnik
Journal:  Ann Transl Med       Date:  2021-04

4.  Transcriptional Repression of MFG-E8 Causes Disturbance in the Homeostasis of Cell Cycle Through DOCK/ZP4/STAT Signaling in Buffalo Mammary Epithelial Cells.

Authors:  Arvind K Verma; Syed A Ali; Parul Singh; Sudarshan Kumar; Ashok K Mohanty
Journal:  Front Cell Dev Biol       Date:  2021-04-01

Review 5.  Lactadherin: From a Well-Known Breast Tumor Marker to a Possible Player in Extracellular Vesicle-Mediated Cancer Progression.

Authors:  Eduardo Durán-Jara; Tamara Vera-Tobar; Lorena De Lourdes Lobos-González
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

6.  Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer.

Authors:  Minwei Bao; Yuxia Huang; Zhongping Lang; Hui Zhao; Yuichi Saito; Tatsuya Nagano; Izumi Kawagoe; Duilio Divisi; Xiaoyi Hu; Gening Jiang
Journal:  Transl Lung Cancer Res       Date:  2022-07

7.  The expression and significance of efferocytosis and immune checkpoint related molecules in pancancer samples and the correlation of their expression with anticancer drug sensitivity.

Authors:  Lin Cheng; Bangbi Weng; Changsheng Jia; Lin Zhang; Bin Hu; Li Deng; Nan Mou; Fengjun Sun; Jing Hu
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

8.  Transcriptome Analysis Reveals MFGE8-HAPLN3 Fusion as a Novel Biomarker in Triple-Negative Breast Cancer.

Authors:  Meng-Yuan Wang; Man Huang; Chao-Yi Wang; Xiao-Ying Tang; Jian-Gen Wang; Yong-De Yang; Xin Xiong; Chao-Wei Gao
Journal:  Front Oncol       Date:  2021-06-15       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.